Wildflower Signs Distribution Agreement with CBD Technologies

VANCOUVER, British Columbia, May 28, 2015: Further to the Company’s news release of May 13, 2015, Wildflower Marijuana Inc. (CSE:SUN) (FWB:RSP) (the "Company") announces that the Company has signed the formal distribution agreement with CBD Technologies, Inc. (“CTI”)  to become the Master Distributor of CTI’s AlcuraÔ product line in Washington State.   Wildflower has placed its first order for product and will receive inventory that will be available for retail outlets within 4 weeks.  The order will consist of a variety of the four different AlcuraÔ disposable CBD vaporizers; 24 hour, Pure, Day and Night.  Descriptions of each vaporizer can be found on CTI’s website at vapealcura.com.

President and CEO William MacLean states, “CTI’s approach to product development is in line with Wildflower’s mandate to produce a great product, using leading technology around an exceptional brand.  Generating revenues in the US market is a key step in the evolution of Wildflower and we look forward to getting our other products on the shelf. ”

Director of Operations, Jeremy Green states, “We believe that in the AlcuraÔ product line we have developed the highest quality hemp-based CBD vapor delivery products on the market.  We look for partners that share our vision for not only our brand but also the market as a whole, and the team at Wildflower is a perfect fit for the AlcuraÔ line.  We are excited to be working with Wildflower to get the products on the shelves in Washington State and beyond.”


Wildflower is a cannabis company focused on developing and designing branded products in the marijuana sector.  In this regard, Wildflower works exclusively in Washington State where such activity is permitted and regulated by State law, through entities which hold licenses for such activities.  Further, Wildflower is advancing two applications to grow and distribute medical marijuana under an MMPR license with Health Canada.  Wildflower’s proprietary growing system is designed to maximize crop yields and consistently produce pure clean pharmaceutical grade BC cannabis for patients and cannabinoid research.

On Behalf of the Board of Directors

William MacLean



William MacLean

Director and CEO